The p53 tumor suppressor protein is a critical regulator of cell cycle progression and apoptosis following exposure of cells to DNA damaging agents such as ionizing radiation or anticancer drugs. An important group of anticancer drugs, including compounds such as etoposide and doxorubicin (Adriamycin), interacts with DNA topoisomerase II (topo II), causing the accumulation of enzyme-DNA adducts that ultimately lead to double-strand breaks and cell death via apoptosis. Human topo IIbeta has previously been shown to interact with p53, and we have extended this analysis to show that both topo IIalpha and IIbeta interact with p53 in vivo and in vitro. Furthermore, we show that the regulatory C-terminal basic region of p53 (residues 364-393) is ...
The tumor suppressor protein p53 and the human DNA topoisomerase I (htopoI) interact with each other...
DNA topoisomerases are the targets of important anticancer and antibacterial drugs. Camptothecins an...
Topoisomerase IIalpha (topo IIalpha) is an important target for several chemotherapeutic agents, inc...
grantor: University of TorontoDNA topoisomerase II (topo II) is an essential nuclear enzym...
p53 tumor suppressor maintains genomic stability, typically acting through cell-cycle arrest, senesc...
p53 tumor suppressor maintains genomic stability, typically acting through cell-cycle arrest, senesc...
Summaryp53 tumor suppressor maintains genomic stability, typically acting through cell-cycle arrest,...
grantor: University of TorontoDNA topoisomerase II (topo II) is a nuclear enzyme that modi...
grantor: University of TorontoDNA topoisomerase II (topo II) is a nuclear enzyme that modi...
Eukaryotic cells store meters of DNA inside nuclei that are less than 10 microns in diameter. Just a...
Topoisomerases are ubiquitous enzymes involved in maintaining genomic stability of the cell by regul...
DNA topoisomerases are ubiquitous nuclear enzymes that govern the topological interconversions of DN...
DNA topoisomerases are ubiquitous nuclear enzymes that govern the topological interconversions of DN...
Gastric cancer is poorly-responsive to widely used antitumour drugs, the efficacy of which is though...
Gastric cancer is poorly-responsive to widely used antitumour drugs, the efficacy of which is though...
The tumor suppressor protein p53 and the human DNA topoisomerase I (htopoI) interact with each other...
DNA topoisomerases are the targets of important anticancer and antibacterial drugs. Camptothecins an...
Topoisomerase IIalpha (topo IIalpha) is an important target for several chemotherapeutic agents, inc...
grantor: University of TorontoDNA topoisomerase II (topo II) is an essential nuclear enzym...
p53 tumor suppressor maintains genomic stability, typically acting through cell-cycle arrest, senesc...
p53 tumor suppressor maintains genomic stability, typically acting through cell-cycle arrest, senesc...
Summaryp53 tumor suppressor maintains genomic stability, typically acting through cell-cycle arrest,...
grantor: University of TorontoDNA topoisomerase II (topo II) is a nuclear enzyme that modi...
grantor: University of TorontoDNA topoisomerase II (topo II) is a nuclear enzyme that modi...
Eukaryotic cells store meters of DNA inside nuclei that are less than 10 microns in diameter. Just a...
Topoisomerases are ubiquitous enzymes involved in maintaining genomic stability of the cell by regul...
DNA topoisomerases are ubiquitous nuclear enzymes that govern the topological interconversions of DN...
DNA topoisomerases are ubiquitous nuclear enzymes that govern the topological interconversions of DN...
Gastric cancer is poorly-responsive to widely used antitumour drugs, the efficacy of which is though...
Gastric cancer is poorly-responsive to widely used antitumour drugs, the efficacy of which is though...
The tumor suppressor protein p53 and the human DNA topoisomerase I (htopoI) interact with each other...
DNA topoisomerases are the targets of important anticancer and antibacterial drugs. Camptothecins an...
Topoisomerase IIalpha (topo IIalpha) is an important target for several chemotherapeutic agents, inc...